Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 253

Results For "patients"

3301 News Found

AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment
Biotech | March 11, 2022

AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment

Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally


Cancer surgeons gather in Delhi to learn new cancer therapies
Public Health | March 11, 2022

Cancer surgeons gather in Delhi to learn new cancer therapies

Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system


First-in-human trial in US for Gan & Lee type 2 diabetes drug
Biotech | March 11, 2022

First-in-human trial in US for Gan & Lee type 2 diabetes drug

The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers


Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals
interviews | March 10, 2022

Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals

As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma


Non-invasive leadless pacemaker implanted in a 60-year-old at Fortis Hospital, Malar
Hospitals | March 10, 2022

Non-invasive leadless pacemaker implanted in a 60-year-old at Fortis Hospital, Malar

The medical team led by Dr. Babu Ezhumalai implanted the dual-chamber leadless pacemaker through a non-surgical procedure successfully


Insilico Medicine and University of Zurich partner to find therapy for Cystinosis
News | March 10, 2022

Insilico Medicine and University of Zurich partner to find therapy for Cystinosis

The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis


Pfizer initiates Phase2/3 study of Paxlovid in pediatric participants
Biotech | March 10, 2022

Pfizer initiates Phase2/3 study of Paxlovid in pediatric participants

Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study


Non-hazardous viral inactivation medium for Covid-19 available in Europe
Medical Device | March 10, 2022

Non-hazardous viral inactivation medium for Covid-19 available in Europe

Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing


Molecular Health and researchers prove new approach to anticipate molecular causation
Biotech | March 10, 2022

Molecular Health and researchers prove new approach to anticipate molecular causation

The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts


Zydus Lifesciences subsidiary Sentynl acquires BridgeBio’s Nulibry
Biotech | March 09, 2022

Zydus Lifesciences subsidiary Sentynl acquires BridgeBio’s Nulibry

Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder